2025年布地奈德缓释胶囊最新价格是多少钱一盒？

Budesonide extended-release capsules are an important drug for the treatment of certain inflammatory diseases. Prices in 2025 vary by region, version and availability. This article will introduce in detail the latest price information, purchase channels and pharmacokinetic properties of budesonide extended-release capsules in 2025.

What is the latest price of a box of budesonide sustained-release capsules in 2025

As of February 2025, it has not been officially launched in China, so the official price cannot be obtained directly from domestic pharmacies or hospital pharmacies. However, for overseas versions of the drug, prices vary depending on the manufacturer, strength and regional differences.

A box of the German version of budesonide sustained-release capsules is 3 mg x 100 capsules, and the price of a box is about US$287. Germany's Dr. Falk Pharma GmbH produces and exports the Turkish version of budesonide in a box of 3mg*100 pills, and the price of a box is about US$192. These prices are for reference only and actual prices may vary due to market fluctuations, exchange rate changes and purchasing channels.

Where to buy budesonide sustained-release capsules

Since budesonide sustained-release capsules have not yet been officially launched in China, patients need to purchase them from abroad through formal channels. At present, purchase channels mainly include the following:

Medical service institutions

Medical service institutions are one of the main ways for patients to obtain unmarketed drugs. Patients can purchase budesonide sustained-release capsules from abroad and mail them to China through international logistics.

Clinical Trial

Another way to obtain budesonide sustained-release capsules is to participate in a clinical trial. Patients participating in the clinical trial have the opportunity to obtain the trial drug for free. However, it should be noted that clinical trials involve certain risks and uncertainties.

Pharmacokinetics of budesonide extended-release capsules

Budesonide extended-release capsules are a non-halogenated glucocorticoid drug with significant local anti-inflammatory effects. Its pharmacokinetic properties are as follows:

Absorption and Distribution

After oral administration of budesonide sustained-release capsules, the drug is first absorbed by the intestine and enters the portal circulation. Because budesonide is poorly absorbed in the intestine, its bioavailability is relatively low.

Budesonide has a large first-pass effect in the liver, which means that most drugs will be metabolized when they pass through the liver for the first time, allowing budesonide sustained-release capsules to release drugs concentratedly in the liver and exert a therapeutic effect on liver lesions.

Metabolism and Excretion

After being metabolized in the liver, budesonide sustained-release capsules enter the systemic circulation, and their metabolites are mainly excreted through urine and feces.

Because budesonide has a long half-life, its efficacy lasts longer and it can continue to exert its anti-inflammatory effect. At the same time, the pharmacokinetic properties of budesonide also determine its distribution and excretion in the body, providing an important reference for clinical medication.